share_log

B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $17

B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $17

B 證券維持對阿米庫斯治療的買入,將目標價格提高至 17 美元
Benzinga ·  2023/03/28 10:24

B of A Securities analyst Tazeen Ahmad maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and raises the price target from $16 to $17.

美國銀行證券分析師塔辛·艾哈邁德維持Amicus Treateutics(納斯達克:折疊)的買入,並將目標價從16美元上調至17美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論